Alphatec (NASDAQ:ATEC) Announces Quarterly Earnings Results

Key Points

• Alphatec reported a quarterly earnings of $0.02 per share, exceeding analyst expectations of ($0.06), with revenues of $185.54 million, higher than the forecast of $178.85 million.
• The company's stock traded up to $13.77 following the earnings report, with a substantial trading volume of 12,995,953 shares.
• Alphatec's price targets have been revised upward by several analysts, with a consensus price target of $18.33 and multiple firms maintaining a "buy" rating.

Alphatec (NASDAQ:ATEC - Get Free Report) posted its quarterly earnings data on Thursday. The medical technology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08, Briefing.com reports. The company had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The firm's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) EPS. Alphatec updated its FY 2025 guidance to EPS.

Alphatec Stock Performance

NASDAQ:ATEC traded down $0.01 during trading hours on Wednesday, reaching $15.34. The company had a trading volume of 1,385,561 shares, compared to its average volume of 2,042,990. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec has a 52 week low of $4.88 and a 52 week high of $15.43. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -13.60 and a beta of 1.05. The firm's 50 day moving average price is $11.47 and its 200-day moving average price is $11.20.

Insider Activity at Alphatec

In other news, EVP Craig E. Hunsaker sold 13,878 shares of Alphatec stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the transaction, the executive vice president owned 1,450,018 shares in the company, valued at $17,922,222.48. This trade represents a 0.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Scott Lish sold 16,666 shares of Alphatec stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total transaction of $249,990.00. Following the transaction, the chief operating officer owned 674,332 shares in the company, valued at $10,114,980. This represents a 2.41% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 389,121 shares of company stock worth $4,929,887. Company insiders own 22.80% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Alphatec by 18.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company's stock valued at $2,696,000 after buying an additional 41,264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Alphatec by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company's stock valued at $750,000 after buying an additional 3,196 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Alphatec during the 1st quarter valued at $257,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays reissued an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research report on Monday. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a research report on Monday, June 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.